Unclear Future for Merck's Insomnia Drug
Yesterday, the Food and Drug Administration's (FDA) advisory committee met to discuss Merck's experimental insomnia drug Suvorexant. While the committee did agree that the drug was effective at lower doses, there were some concerns over the side-effects associated with the medication at higher doses. In the following video, health-care analyst Max Macaluso discusses the results of the meeting, and how the ultimate FDA decision on Suvorexant can impact Merck's stock.
Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013, and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more, click here to claim your copy today.
The article Unclear Future for Merck's Insomnia Drug originally appeared on Fool.com.Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.